Correction: Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]
-
* Corresponding author: Trevor Powles hdummer@parkside-hospital.co.uk
1 Parkside Oncology, London, UK
2 Tom Baker Cancer Centre, Calgary, Alberta, Canada
3 WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK
4 Department of Clinical Pharmacology, University of Oxford, Oxford, UK
5 Scheffler Group, Villanova, Pennsylvania, USA
6 Royal Marsden Hospital, London, UK
7 Radium Institute, Oslo, Norway
Breast Cancer Research 2006, 8:406 doi:10.1186/bcr1413
Published: 3 May 2006First paragraph (this article has no abstract)
It has been brought to our attention that there was a typographical error in our recent article [1] published in March 2006.